Elevated Level of Blood Lysosphingolipids in Patients with Schizophrenia-Reference-Cited by-同舟云学术

Elevated Level of Blood Lysosphingolipids in Patients with Schizophrenia

Published:2023-06-01 Issue:6 Volume:59 Page:670-675
ISSN:0016-6758
Container-title:Генетика
language:
Short-container-title:Genetika

Author:

Kopytova A. E.¹²,Usenko T. S.¹²,Bezrukova A. I.²,Basharova K. S.²,Andreeva T. V.³⁴⁵,Volkova E. V.¹,Manakhov A. D.³⁴⁵,Baydakova G. V.⁶,Palchikova E. I.⁷,Zakharova E. Yu.⁶,Zalutskaya N. M.⁷,Neznanov N. G.¹⁷,Pchelina S. N.¹²

Affiliation:

1. Pavlov First Saint-Petersburg State Medical University

2. Konstantinov Petersburg Nuclear Physics Institute of National Research Centre “Kurchatov Institute”

3. Vavilov Institute of General Genetics Russian Academy of Sciences

4. Center of Genetics and Genetic Technologies, Lomonosov Moscow State University

5. Sirius University of Science and Technology

6. Research Center for Medical Genetics

7. Bekhterev National Medical Research Center Psychiatry and Neurology

Abstract

Schizophrenia is a mental disorder with a prevalence of 0.7–1% of the general population and is characterized by impaired dopamine transmission in neurons. Recent data have shown that lysosomal storage disorders (LSD), characterized by a decrease in enzyme activity and a corresponding accumulation of substrate in lysosomes due to mutations in lysosomal genes, can manifest a wide range of clinical symptoms including psychosis, affective disorders, early onset dementia and schizophrenia. The purpose of this study was to assess the level of lysosphingolipids in patients with schizophrenia, Parkinson’s disease (PD) and control. The study included 52 patients with schizophrenia, 170 patients with PD patients and 166 neurologically healthy individuals (control group). Concentration of lysosomal substrates (hexosylsphingosine (HexSph), globotriaosylsphingosine (LysoGb3), lysosphingomyelin (LysoSM)) were measured by high-liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) in blood. An increase in the concentration of LysoSM, LysoGb3, HexSph was detected in patients with schizophrenia compared to control (p 0.0001, p 0.0001, p 0.0001, respectively). Our results confirm a violation of the lysosphingolipid composition of the blood in patients with schizophrenia.

Publisher

The Russian Academy of Sciences

Reference29 articles.

1. Howrigan D.P., Rose S.A., Samocha K.E. et al. Exome sequencing in schizophrenia-affected parent–offspring trios reveals risk conferred by protein-coding de novo mutations // Nat. Neurosci. 2020. V. 23. P. 185–193. https://doi.org/10.1038/s41593-019-0564-3

2. Oh J., Shen G., Nan G. et al. Comorbid schizophrenia and Parkinson’s disease: A case series and brief review // Neurol. Asia. 2017. V. 22. P. 139–142.

3. Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review // Theor. Adv. Psychopharmacol. 2013. V. 3. № 1. P. 33–51. https://doi.org/10.1177/2045125312464385

4. Castillo R.I., Rojo L.E., Henriquez-Henriquez M. et al. From molecules to the clinic: Linking schizophrenia and metabolic syndrome through sphingolipids metabolism // Front. Neurosci. 2016. V. 10. P. 488–503. https://doi.org/10.3389/fnins.2016.00488

5. Pardiñas A.F., Holmans P., Pocklington A.J. et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection // Nat. Genet. 2018. V. 50. P. 381–389.